Pages that link to "Q36077365"
The following pages link to A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. (Q36077365):
Displaying 50 items.
- Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies (Q22251051) (← links)
- Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses (Q26771515) (← links)
- Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems (Q26786247) (← links)
- Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors (Q28273285) (← links)
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis (Q28303010) (← links)
- Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis (Q28483930) (← links)
- Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine. (Q30383064) (← links)
- Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats (Q30397210) (← links)
- Differentiation of schizophrenia patients from healthy subjects by mismatch negativity and neuropsychological tests (Q30468652) (← links)
- Pharmacologic Treatment with GABA(B) Receptor Agonist of Methamphetamine-Induced Cognitive Impairment in Mice (Q30474281) (← links)
- Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. (Q30482602) (← links)
- Molecular targets for treating cognitive dysfunction in schizophrenia. (Q30491310) (← links)
- Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist (Q30524240) (← links)
- Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research (Q30582343) (← links)
- Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort (Q30835228) (← links)
- Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data (Q33521559) (← links)
- Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies (Q33535963) (← links)
- The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia. (Q33605308) (← links)
- Evidence for an immune role on cognition in schizophrenia: a systematic review (Q33621692) (← links)
- Effect of second-generation antipsychotics on cognition: current issues and future challenges (Q33888153) (← links)
- Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients (Q33936458) (← links)
- Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia (Q33976994) (← links)
- Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol (Q34041023) (← links)
- Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia (Q34082617) (← links)
- The Role of Rodent Models in The Discovery of New Treatments for Schizophrenia: Updating Our Strategy (Q34140126) (← links)
- Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. (Q34145251) (← links)
- Cognition in schizophrenia: Past, present, and future (Q34224025) (← links)
- A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia (Q34224372) (← links)
- Development of a virtual reality assessment of everyday living skills (Q34242847) (← links)
- The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. (Q34252311) (← links)
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents (Q34274859) (← links)
- Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. (Q34379248) (← links)
- Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review (Q34436237) (← links)
- Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial (Q34486230) (← links)
- Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs (Q34541147) (← links)
- Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies (Q34590400) (← links)
- Effects of risperidone on procedural learning in antipsychotic-naive first-episode schizophrenia (Q34656464) (← links)
- Antipsychotic drugs for first-episode schizophrenia: a comparative review (Q34659096) (← links)
- Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond (Q34783420) (← links)
- T102C polymorphism of serotonin-2A receptor gene in Turkish schizophrenia patients: Association with cognitive impairment and soft neurological signs. (Q34786246) (← links)
- Diabetes and cognitive deficits in chronic schizophrenia: a case-control study (Q34805258) (← links)
- Analyzing the influence of BDNF heterozygosity on spatial memory response to 17β-estradiol (Q35034804) (← links)
- Executive control in chronic schizophrenia: A perspective from manual stimulus-response compatibility task performance (Q35037037) (← links)
- Recovery of behavioral changes and compromised white matter in C57BL/6 mice exposed to cuprizone: effects of antipsychotic drugs (Q35087719) (← links)
- Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia (Q35110274) (← links)
- Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine (Q35171349) (← links)
- How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library (Q35213673) (← links)
- Neuropsychology, autobiographical memory, and hippocampal volume in "younger" and "older" patients with chronic schizophrenia (Q35505540) (← links)
- The relationship between sleep-wake cycle and cognitive functioning in young people with affective disorders (Q35512724) (← links)
- Relationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses (Q35577541) (← links)